Board of Directors

Per Wold-Olsen
Per Wold-Olsen
MBA, Chairman

Per Wold-Olsen was appointed as Chairman of the Board in 2018.

Per has a extensive experience in the pharmaceutical industry and has held many different positions within Merck & CO Inc.. He was served on Merck’s management team between 1994-2006. Since 2006 has served on several boards including Lundbeck, Pharmaset and Royal Dutch Numico.

Per holds a MBA. in Economics and Administration from Handelshøyskolen BI and a MBA. in Management and Marketing from the University of Wisconsin.

Born: 1947
Board Committees: Chairman of the Remuneration Committee and member of the Audit and Nomination Committee
Holdings in Oncopeptides: 49,317 shares and 13,051 Share Awards**
Other current positions: Chairman of the Board of MMV (Medicines for Malaria Venture) and GN Store Nord A/S. He is also a Board member of Gilead Sciences, Inc.

Independent in relation to the Company and its management and in relation to major shareholders.

Brian Stuglik
Brian Stuglik
B.Pharm, Board member

Brian Stuglik was appointed to the Board of Oncopeptides 2018.

Brian has a long and broad experience in the pharmaceutical industry. He worked for 30 years in different positions within the pharmaceutical company Eli Lilly, both with American as well as global focus and responsibilities. Over the past 25 years, his work has been focused on product strategy and commercialization for oncological products.

Brian holds a Bachelor of Pharmacy from Purdue University, US.

Born: 1959
Holdings in Oncopeptides: 5,220 Share Awards**
Other current positions: Brian is the founder of, and since 2016 runs, ProventusHealth Care Solutions LLC. He is a member of the American Society of Clinical Oncology, the American Association for Cancer Research and the International Association for Lung Cancer Studies. Brian is also a board member and chairman of the Remuneration Committee for Verastem Inc.

Independent in relation to the Company and its management and in relation to major shareholders.

Cecilia Daun Wennborg
Cecilia Daun Wennborg
MSc, Board member

Cecilia Daun Wennborg was appointed to the board of Oncopeptides in 2017.

Cecilia has 14 years of experience from board positions in listed companies. 20 years of experience from operational positions in the insurance, bank and care and healthcare sectors, inter alia as CFO and CEO of Skandia Link, head of Skandia Sverige, CFO of Carema Vård & Omsorg AB and Ambea AB, CEO of Carema Vård & Omsorg AB and deputy CEO of Ambea AB.

She was also ordinary member and chairman of the board of directors in Randstad AB (previously Proffice Aktiebolag), board member in Carnegie Fonder AB, Eniro AB, Ikano Bank AB (publ), Aktiebolaget Svensk Bilprovning and Kvinvest AB.

Cecilia holds a MSc in Business and Economics from Stockholm University.

Born: 1963
Board Committees: Chairman of the Audit Committee
Holdings in Oncopeptides: 6,000 shares and 11,020 Share Awards**
Other current assignments: Member of the board of directors in Getinge AB, Bravida Holding AB, ICA Gruppen AB, Loomis AB, Atvexa AB, Insamlingsstiftelsen Oxfam Sverige, Sophiahemmet AB and the non-profit organisation Sophiahemmet, Hotel Diplomat AB and CDW Konsult AB. Member of the Swedish Securities Council.

Independent in relation to the Company and its management and in relation to major shareholders.

Jarl Ulf Jungnelius
Jarl Ulf Jungnelius
MD, PhD, Board member

Jarl Ulf Jungnelius was appointed to the board of Oncopeptides in 2011.

Ulf is a licensed medical practitioner and a specialist in a number of areas including oncology. He has published a number of scientific articles and has more than 25 years’ experience in leadership positions in both large academic and corporate institutions.

He has been instrumental in the development and registration of gemcitabine (Gemzar), premetrexed (Alimta), Sunitinib (Sutent), lenalidomide (Revlimid) and the albumin bound nanoparticle paclitaxel (Abraxane).

Born: 1951
Holdings in Oncopeptides: 7,850 shares, 49 Employee Options* and 11,020 Share Awards**
Other current positions: Director Biovica International AB, Isofol Medical AB, Monocl AB, Noxxon AG and HealthCom GmbH.

Independent in relation to the Company and its management and in relation to major shareholders.

Jennifer Jackson
Jennifer Jackson
PhD, Board member

Jennifer Jackson was appointed to the board of Oncopeptides in 2018.

Jennifer Jackson is a US citizen. Jennifer is Senior Vice President of Regulatory Affairs and Quality Assurance and a member of the executive leadership team at TESARO, a US oncology-focused biopharmaceutical company. She has more than twenty-five years of experience in global clinical development and market registration of small molecules and biologics across multiple therapeutic areas including oncology. At TESARO, Jennifer built the Regulatory Affairs and Quality functions and was instrumental in the US breakthrough designation, US and EU orphan designations and US and EU approvals of ZEJULA for maintenance treatment of ovarian cancer.

Prior to TESARO, Jennifer was Senior Vice President, Regulatory Affairs at Cubist Pharmaceuticals as well as various senior regulatory roles at Biogen, Vertex and Bristol-Myers Squibb. In her regulatory roles, she has gained broad experience from interacting with the FDA, EMA and other international regulatory authorities to guide drug development from laboratory discovery to product approval and commercialization.

Jennifer earned her Ph.D. in Genetics at Cornell University and did her postdoctoral work at Massachusetts Institute of Technology. She is a member of the American Society of Clinical Oncology.

Born: 1953
Holdings in Oncopeptides: 2,170 Share Awards**
Other current positions: Senior Vice President of Regulatory Affairs and Quality Assurance and a member of the executive leadership team at TESARO.

Independent in relation to the Company and its management and in relation to major shareholders.

Jonas Brambeck
Jonas Brambeck
PhD, Board member

Jonas Brambeck was appointed to the board of Oncopeptides in 2008.

In addition to being a board member of Oncopeptides, Jonas is an Investment Manager at Industrifonden, a leading Nordic venture capital fund, and a member of the Board of Directors of the life sciences companies Oxthera AB and Avidicare AB (deputy).

He has previously held positions at a number of life sciences businesses including AstraZeneca, Bruker Instruments and Nobel.

Jonas holds a PhD in organic chemistry from The Royal Institute of Technology in Stockholm.

Born: 1958
Board Committees: Member of the Remuneration Committee and Audit Committee
Holdings in Oncopeptides: Nil
Other current positions: Board member in Avidicare AB (deputy), Airsonett AB (deputy), OxThera AB and OxThera Intellectual Property AB.

Independent in relation to the Company and its senior management, but not in relation to major shareholders. Employee of Industrifonden Foundation (Stiftelsen Industrifonden).

Olof Tydén
Olof Tydén
MD, PhD, Board member

Olof Tydén was appointed to the board of Oncopeptides in 2014.

In addition to his directorship with Oncopeptides, Olof is a Partner at Eureda, an international pharmaceutical consulting firm.

Olof has previously held positions as Medical Director at Leo Pharmaceuticals and Kabi-Vitrum (now Pfizer) and Programme Director at the Medical Products Agency in Sweden. Olaf was for six years Senior Regulatory Adviser at Hoffman-La Roche with responsibility for EU strategies, knowledge management and training. In 2000 he founded Eureda, a strategic regulatory consultancy. Olof has also served as an expert to the European Commission in Health Telematics and has been a member of the board of life sciences companies Bioxell SpA, Aprea AB, Cantargia AB and Ximmune AB.

Olof holds a PhD from Uppsala University and an associate professorship in obstetrics and gynaecology at Uppsala University.

Born: 1947
Holdings in Oncopeptides: 1,000 shares, 49 Employee Options* and 11,020 Share Awards**
Other current positions: Director of Eureda AB. Alternate Director of Uppsala Medical Information AB.

Independent in relation to the Company and its management and in relation to major shareholders.

Per Samuelsson
Per Samuelsson
MSc, Board member

Per Samuelsson was appointed to the board of Oncopeptides in 2012.

In addition to being a board member of Oncopeptides, Per is a partner at HealthCap, a life sciences venture capital business.

Per has over 15 years investment banking experience, mainly with Aros Securities based in Sweden. At Aros Securities he held a number of roles including being a Director in the corporate finance department where he specialized in merger transactions, initial public offerings and equity incentive programs. Per also held the role of Head of Research at Aros Securities.

Per holds an MSc in Engineering from the Institute of Technology in Linköping, Sweden.

Born: 1961
Board Committees: Member of the Audit Committee and the Remuneration Committee
Holdings in Oncopeptides: Nil
Other current positions: Director of Ancilla AB, Cantando AB, Cantando Holding AB, HealthCap AB, HealthCap Annex Fund I-II GP AB, HealthCap Orx Holdings GP AB, HealthCap 1999 GP AB, HealthCap III Sidefund GP AB, HealthCap IV GP AB, RSPR Pharma AB, Skipjack AB, SwedenBIO Service AB, Nordic Nanovector ASA och Targovax ASA.

Independent in relation to the Company and its senior management, but not in relation to major shareholders. Partner in HealthCap and holder of directorships in a number of companies within the HealthCap Group.

* Each employee option entitles the holder to acquire 900 shares per option in the company.
** One share award entitles to one share in accordance with existing terms.
For more information and terms please read under Corporate Governance – Remuneration.

Holdings in Oncopeptides AB as of March 19, 2019.